Investigation of cancer cell lines for peptide receptor-targeted drug development

References

• Anthony CT, Hughey S, Lyons J, Weiss S, Hornick CA, Drouant GJ, Fuselier JA, Coy DH, Murphy WA, Woltering EA. (2004). The effect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs. J Surg Res, 119, 1–13.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Senter PD. (2008). Antibody–drug conjugates for cancer therapy. Cancer J, 14, 154–169.
   PubMed Web of Science ®Google Scholar
• Eden PA, Taylor JE. (1993). Somatostatin receptor subtype gene expression in human and rodent tumors. Life Sci, 53, 85–90.
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV, Dietl J, Rieger L, Hönig A. (2007). Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm, 4, 652–658.
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G. (2005). Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer, 12, 999–1009.
   PubMed Web of Science ®Google Scholar
• Feron O. (2010). Tumor-penetrating peptides: a shift from magic bullets to magic guns. Sci Transl Med, 2, 34ps26.
   PubMedGoogle Scholar
• Fuselier JA, Sun L, Woltering SN, Murphy WA, Vasilevich N, Coy DH. (2003). An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett, 13, 799–803.
   PubMed Web of Science ®Google Scholar
• Garrison JB, Shaw YJ, Chen CS, Kyprianou N. (2007). Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res, 67, 11344–11352.
   PubMed Web of Science ®Google Scholar
• Goldbard S. (2006). Bringing primary cells to mainstream drug development and drug testing. Curr Opin Drug Discov Devel, 9, 110–116.
   PubMed Web of Science ®Google Scholar
• Hohla F, Buchholz S, Schally AV, Krishan A, Rick FG, Szalontay L, Papadia A, Halmos G, Koster F, Aigner E, Datz C, Seitz S. (2010). Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Lett, 294, 35–42.
   PubMed Web of Science ®Google Scholar
• Horrocks C, Halse R, Suzuki R, Shepherd PR. (2003). Human cell systems for drug discovery. Curr Opin Drug Discov Devel, 6, 570–575.
   PubMed Web of Science ®Google Scholar
• Ioannou M, Papagelopoulos PJ, Papanastassiou I, Iakovidou I, Kottakis S, Demertzis N. (2008). Detection of somatostatin receptors in human osteosarcoma. World J Surg Oncol, 6, 99.
   PubMedGoogle Scholar
• Kamb A. (2005). What’s wrong with our cancer models? Nat Rev Drug Discov, 4, 161–165.
   PubMed Web of Science ®Google Scholar
• Khanna G, Bushnell D, O’Dorisio MS. (2008). Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors. Oncologist, 13, 382–389.
   PubMed Web of Science ®Google Scholar
• Knutsson M, Edvinsson L. (2002). Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport, 13, 507–509.
   PubMed Web of Science ®Google Scholar
• Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Oberg K, Janson ET. (2004). Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells. Med Oncol, 21, 285–295.
   PubMed Web of Science ®Google Scholar
• Ma C. (2004). Animal models of disease. Modern Drug Discov, 7, 30–34.
   Google Scholar
• Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. (2008). Tumor receptor imaging. J Nucl Med, 49 (Suppl 2), 149S–163S.
   PubMed Web of Science ®Google Scholar
• Mezo G, Manea M. (2010). Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv, 7, 79–96.
   PubMed Web of Science ®Google Scholar
• Moody TW, Sun LC, Mantey SA, Pradhan T, Mackey LV, Gonzales N, Fuselier JA, Coy DH, Jensen RT. (2006). In vitro and in vivo antitumor effects of cytotoxic camptothecin–bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther, 318, 1265–1272.
   PubMed Web of Science ®Google Scholar
• Nanda PK, Lane SR, Retzloff LB, Pandey US, Smith CJ. (2010). Radiolabeled regulatory peptides for imaging and therapy. Curr Opin Endocrinol Diabetes Obes, 17, 69–76.
   PubMed Web of Science ®Google Scholar
• Panetta R, Patel YC. (1995). Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci, 56, 333–342.
   PubMed Web of Science ®Google Scholar
• Patel YC. (1999). Somatostatin and its receptor family. Front Neuroendocrinol, 20, 157–198.
   PubMed Web of Science ®Google Scholar
• Rangarajan A, Weinberg RA. (2003). Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer, 3, 952–959.
   PubMed Web of Science ®Google Scholar
• Reubi JC. (2003). Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev, 24, 389–427.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. (2000). Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res, 60, 3105–3112.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Maecke HR. (2008). Peptide-based probes for cancer imaging. J Nucl Med, 49, 1735–1738.
   PubMed Web of Science ®Google Scholar
• Schally AV, Nagy A. (1999). Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol, 141, 1–14.
   PubMed Web of Science ®Google Scholar
• Schally AV, Nagy A. (2003). New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci, 72, 2305–2320.
   PubMed Web of Science ®Google Scholar
• Shoemaker RH, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, Covell DG, Sausville EA. (2002). Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem, 2, 229–246.
   PubMedGoogle Scholar
• Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. (2010). The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med, 51, 875–882.
   PubMed Web of Science ®Google Scholar
• Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, Vessella R. (2006). Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int J Cancer, 118, 222–229.
   PubMed Web of Science ®Google Scholar
• Sun B, Schally AV, Halmos G. (2000). The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept, 90, 77–84.
   PubMed Web of Science ®Google Scholar
• Sun L, Coy DH. (2008). Cytotoxic conjugates of peptide hormones for cancer chemotherapy. Drugs Future, 33, 217–223.
   Web of Science ®Google Scholar
• Sun L, Fuselier JA, Coy DH. (2004a). Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents. Drug Deliv, 11, 231–238.
   PubMed Web of Science ®Google Scholar
• Sun L, Mackey LV, Luo J, Fuselier JA, Coy DH. (2008). Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol, 2, 491–499.
   PubMedGoogle Scholar
• Sun L, Vasilevich NI, Fuselier JA, Coy DH. (2004b). Abilities of 3,4-diarylfuran-2-one analogs of combretastatin A-4 to inhibit both proliferation of tumor cell lines and growth of relevant tumors in nude mice. Anticancer Res, 24, 179–186.
   PubMed Web of Science ®Google Scholar
• Sun L, Vasilevich NI, Fuselier JA, Hocart SJ, Coy DH. (2004c). Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg Med Chem Lett, 14, 2041–2046.
   PubMed Web of Science ®Google Scholar
• Sun LC, Luo J, Mackey VL, Fuselier JA, Coy DH. (2007). Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs, 18, 341–348.
   PubMed Web of Science ®Google Scholar
• Szepeshazi K, Schally AV, Nagy A, Halmos G. (2005). Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Pancreas, 31, 275–282.
   PubMed Web of Science ®Google Scholar
• Teicher BA. (2009). Antibody-drug conjugate targets. Curr Cancer Drug Targets, 9, 982–1004.
   PubMed Web of Science ®Google Scholar
• Weinstein JN. (2006). Spotlight on molecular profiling: “integromic” analysis of the NCI-60 cancer cell lines. Mol Cancer Ther, 5, 2601–2605.
   PubMed Web of Science ®Google Scholar
• Xiao D, Wang J, Hampton LL, Weber HC. (2001). The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene, 264, 95–103.
   PubMed Web of Science ®Google Scholar
• Zwanziger D, Beck-Sickinger AG. (2008). Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr Pharm Des, 14, 2385–2400.
   PubMed Web of Science ®Google Scholar